Soleno Therapeutics Inc's Competitiveness
A competitive positioning analysis and financial ratio benchmarking of Soleno Therapeutics Inc (SLNO) against its publicly traded competitors: sales growth, net income, profitability, valuation and market share, plus each peer's market capitalization, revenue, income and employees. Free below: the top 5 peers. Subscriber access adds the full competitor list and CSV downloads.
Key Findings: Soleno Therapeutics Inc vs Its Competitors
- TTM: Trailing 12-month revenue of 285M vs 37M combined for its competitors (88.5% combined share).
- Trending: Latest-quarter revenue run-rate is accelerating (+32.8% annualized vs trailing 12 months), vs decelerating (-74.1%) for its tracked peer group.
- Profitability: Its 33.2% net margin compares with -1,834.0% for the peer group.
- Peer revenue share: Soleno Therapeutics Inc accounted for 97.5% of combined revenue among its tracked peer group.
- Peer differentiation: Revenue per employee of $1.57M compares with $0.84M for the peer group (1.9x).
Every figure above is sourced and cited in detail further down this page (Market Structure, Profitability & Cost Structure, Productivity vs Peers).
SLNO Sales vs. its Competitors, Q1 2026
With a net margin of 33.17 %, Soleno Therapeutics Inc achieved higher profitability than its competitors (-1,833.97 %).
Soleno Therapeutics Inc generated 97.52 % of the combined sales of its peer group.
API endpoints for this dataset
Soleno Therapeutics Inc vs. its Competitors, Q1 2026
Net margin
Revenue run-rate vs trailing 12 months
TTM net margin
TTM = trailing twelve months. Run-rate annualizes the latest quarter (×4) and compares it to TTM. In millions of $. High-Confidence Competitors are named as a competitor directly in Soleno Therapeutics Inc reports; Similar-Size Competitors are the closest peers by market-cap rank within the same industry; Similar Growth & Profitability Competitors are the closest peers by combined revenue growth, operating margin and ROIC, all independent of the competitor list.
TTM revenue, latest-quarter run-rate and net income/margin benchmarked across Soleno Therapeutics Inc and its 4 competitor groupings. Available under Commercial License.
| Entity | TTM Revenue | Rev Run-rate vs TTM |
|---|---|---|
| Soleno Therapeutics Inc | $12,345M | +12.3% · Accelerating |
| Competitors combined | $12,345M | +12.3% · Accelerating |
| High-Confidence Competitors (1) | $12,345M | +12.3% · Accelerating |
TTM revenue, run-rate and net margin benchmarking across Soleno Therapeutics Inc's competitor groups requires a Commercial License.
Soleno Therapeutics Inc's Competitor Quality Breadth
Group definitions: see Methodology: Performance Group Definitions.
| Entity | Profitable | Expanding | Above Industry Growth | Distressed |
|---|---|---|---|---|
| Soleno Therapeutics Inc | Yes | - | - | No |
| Competitors combined (3) | ||||
| High-Confidence Competitors (1) |
Source: CSIMarket API, trailing 12 months. Altman Z-Score is not shown here: it is not populated in the underlying data for any company. Percentages are of companies in each group that report the relevant metric, not of the full group size.
SLNO Stock Performance relative to its Competitors
SLNO Stock Performance relative to High-Confidence Competitors
5 Best-Performing Tracked Competitors, Trailing 12 Months
| # | Competitor | TTM Share Price Return | vs U.S.A. 500 |
|---|---|---|---|
| 1 | Amicus Therapeutics inc | 282.9% | Outperformed |
| 2 | Zymeworks Inc | 282.9% | Outperformed |
TTM share price return and U.S.A. 500 outperformance for Soleno Therapeutics Inc's best-performing competitors requires a Commercial License.
Source: CSIMarket API, trailing 12 months.
Soleno Therapeutics Inc's Comment on Competition and Industry Peers
Publicly Traded Peers of Soleno Therapeutics Inc
Revenue and income for trailing 12 months, in millions of $, except employees| Company | Market Cap | Revenues |
|---|---|---|
 Soleno Therapeutics Inc |
2,813.08 | 285.01 |
 Amicus Therapeutics inc |
4,468.19 | 632.83 |
 Zymeworks Inc |
2,183.96 | 37.13 |
 Ocean Biomedical Inc |
0.02 | - |
| SUBTOTAL | 9,465.25 | 954.96 |
Sources: see Methodology: Peer & Competitor Identification, Sourcing.
Updated on:
Focus of this report: publicly traded companies. Ten additional tables on Soleno Therapeutics Inc versus competitors, including market share analysis, are in the navigation menu under Competition. To download the tables, please subscribe.
Soleno Therapeutics Inc's Competitors Named by the Company
Competitive relationships identified from Soleno Therapeutics Inc reports and corroborating sources, each with a basis and confidence.| Competitor | Basis | Confidence |
|---|---|---|
| Harmony Biosciences Holdings inc | Company report | 85% |
| Amicus Therapeutics inc | Company report | 85% |
Company report basis, confidence, active dates and source counts for Soleno Therapeutics Inc's named competitors require a Commercial License.
Methodology: see Methodology: Peer & Competitor Identification, Sourcing.
Soleno Therapeutics Inc's Productivity vs Peers Comparison
Revenue and income per employee, trailing 12 months, in $; market cap in millions of $| Company | Market Cap | Revenue / Employee | Income / Employee |
|---|---|---|---|
| Soleno Therapeutics Inc | 2,813 | 1,565,978 | 527,692 |
| Amicus Therapeutics inc | 4,468 | 1,238,411 | -53,053 |
| Zymeworks Inc | 2,184 | 140,633 | -568,152 |
| Ocean Biomedical Inc | 0 | - | -1,234,500 |
| PEERS TOTAL | 6,652 | 840,596 | -256,287 |
Soleno Therapeutics Inc's Position in Industry Market Structure
Market-capitalization share and concentration across all 218 companies in Soleno Therapeutics Inc's industry classification, broader than the peer set above. Market cap in millions of $.Soleno Therapeutics Inc ranks #0 of 218 companies by market capitalization in its industry, holding 0.00 % of total industry market cap. The industry's Herfindahl-Hirschman Index (HHI) is 615, indicating a unconcentrated market structure (see Methodology: Market Structure & Concentration).
| Rank | Company | Market Cap | Industry Share |
|---|---|---|---|
| 1 | Intuitive Surgical Inc | 163,695 | 13.56 % |
| 2 | Medtronic Plc | 131,665 | 10.91 % |
| 3 | Stryker Corp | 126,732 | 10.50 % |
| 4 | 3m Company | 97,260 | 8.06 % |
| 5 | Boston Scientific Corporation | 1,234 | 5.2% |
| 6 | Edwards Lifesciences Corporation | 1,234 | 5.2% |
| 7 | Becton Dickinson And Company | 1,234 | 5.2% |
| 8 | Alcon inc | 1,234 | 5.2% |
| 9 | Medline Inc | 1,234 | 5.2% |
| 10 | Resmed Inc | 1,234 | 5.2% |
| 0 | Soleno Therapeutics Inc | 2,813 | 0.00 % |
Market cap and industry share for the rest of Soleno Therapeutics Inc's industry peers requires a Commercial License.
Source: CSIMarket API (daily market-structure computation) across CSIMarket's industry classification, market capitalization as of 2026-05-18.
Soleno Therapeutics Inc's Profitability & Cost Structure
Trailing 12-month margins from SEC-filed financials. Operating margin is compared to the Medical Equipment & Supplies industry median; gross margin, EBITDA margin and capital intensity are compared to the live industry average (342 companies). See the full Medical Equipment & Supplies industry profitability benchmarks.| Metric | Company | Industry | Difference |
|---|---|---|---|
| Gross Margin | 98.63 % | 46.19 % (avg) | +52.4 pp |
| Operating Margin | 30.33 % | industry median | +32.6 pp |
| EBITDA Margin | 33.46 % | -6.72 % (avg) | +40.2 pp |
| Capital Intensity (Capex / Revenue) | 0.04 % | 7.15 % (avg) | -7.1 pp |
Source: CSIMarket API, trailing 12 months. SG&A and R&D as a share of revenue have limited coverage as this data is backfilled and appear only where reported. Higher capital intensity is not inherently negative; it reflects the industry's asset requirements.
Soleno Therapeutics Inc's Valuation vs Competitive Position
Valuation multiples vs the Medical Equipment & Supplies industry average (342 companies, excluding loss-making/negative-equity outliers), alongside returns on capital for context on whether a premium or discount lines up with measurably stronger or weaker returns. See the full Medical Equipment & Supplies industry valuation benchmarks.| Metric | Company | Industry Average | Difference |
|---|---|---|---|
| P/E | 21.8x | 36.6x | -14.8x |
| EV / EBITDA | 21.0x | 17.7x | +3.2x |
| P/B | 5.0x | 4.6x | +0.4x |
| Return on Equity | 22.85 % | industry aggregate | 14.62 % |
| Return on Invested Capital | 9.47 % | -6.79 % (avg) | 16.26 % |
Source: CSIMarket API, trailing 12 months. A valuation premium or discount is not, by itself, a judgment of over- or under-valuation. Compare it against the return and growth context shown elsewhere on this page.
Soleno Therapeutics Inc's Multi-Year Financial Trajectory
Fiscal-year revenue growth, operating margin, return on invested capital and P/E, as reported in company reports.| Metric | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|---|
| Revenue Growth | - | - | - | - | - | - | - | - |
| Operating Margin | - | - | - | - | - | - | - | - |
| Return on Invested Capital | -25.48 % | -47.06 % | -35.89 % | -44.03 % | -51.45 % | -35.61 % | -36.92 % | 1.19 % |
| P/E | - | - | - | - | - | - | - | 210.9x |
Source: CSIMarket API, fiscal-year figures. P/E is this company's own historical ratio at each fiscal year end and can swing sharply around an earnings trough: that is real, not a data error.
Soleno Therapeutics Inc's Competitive Forces (Porter's Five Forces)
Only the forces this data can support honestly are shown; the other three are marked as such rather than guessed.| Force | Assessment | Basis |
|---|---|---|
| Competitive Rivalry | High | Industry HHI of 615 (see Industry Market Structure & Concentration above) |
| Barriers to Entry | Lower than typical for the industry | Capital intensity (capex / revenue) of 0.04 % vs industry average 7.15 % (see Profitability & Cost Structure above) |
Note: see Methodology: Porter's Five Forces. Supplier power and buyer power are covered on Soleno Therapeutics Inc's dedicated Suppliers and Customers pages, not here.
Soleno Therapeutics Inc's Industry Attractiveness & Competitive Strength
See Methodology: GE/McKinsey Matrix for how the two axes are built.
Soleno Therapeutics Inc falls in the Low attractiveness / High strength cell: Selective.
Source: CSIMarket API, trailing 12 months. Each axis score is a simple 1(low)/2(medium)/3(high) average across its three inputs -- a transparent, disclosed simplification, not a validated academic scoring model.
Soleno Therapeutics Inc's SWOT
Every point below is a fixed rule applied to a metric already shown elsewhere on this page (Market Structure, Profitability, Valuation, Run-Rate, Stock Performance, Quality Breadth) not an independent strategic assessment. A blank quadrant means no rule was met, not that none apply.Strengths
- Operating margin 32.6 points above the industry median.
- Return on equity 14.6 points above the industry aggregate.
- Latest-quarter revenue run-rate is accelerating (+32.8% annualized vs trailing 12 months).
Weaknesses
- Underperforming the U.S.A. 500 over the trailing 12 months.
Opportunities
- Trades at a lower P/E than the industry average (21.8x vs 36.6x) despite a higher return on invested capital -- a possible re-rating opportunity.
- A meaningful share of competitors (33.30 %) show financial-distress signals, a possible opening to gain share.
Threats
- Tracked peer group's revenue run-rate is broadly decelerating (-74.1% annualized).
Methodology: see Methodology: SWOT Analysis.
Soleno Therapeutics Inc's Financial Strength vs Peers Comparison
Quick ratio, working capital, debt to equity and asset turnover, trailing 12 months| Company | Quick Ratio | Working Capital | Debt / Equity |
|---|---|---|---|
| Soleno Therapeutics Inc | 3.03 | 8.84 | 0.12 |
| Amicus Therapeutics inc | 0.98 | 3.06 | 1.74 |
| Zymeworks Inc | 3.17 | 7.32 | - |
| Ocean Biomedical Inc | 0.00 | 0.04 | - |
Quick ratio = cash / current liabilities; working capital ratio = current assets / current liabilities; asset turnover = revenue / total assets. Peers in the Blank Checks industry are excluded.
Soleno Therapeutics Inc's Revenue and Income Growth vs Peers
Quarterly revenue and net income growth, year over year and quarter over quarter| Company | Period | Revenue Y/Y | Income Y/Y |
|---|---|---|---|
| Soleno Therapeutics Inc | Q1 2026 | - | - |
| Amicus Therapeutics inc | Q4 2025 | +23.7 % | -88.5 % |
| Zymeworks Inc | Q2 2026 | -90.6 % | - |
| Ocean Biomedical Inc | Q1 2025 | - | - |
| PEERS TOTAL | +43.3 % | - |
Growth is shown only where both periods are positive. Peers in the Blank Checks industry are excluded.
Soleno Therapeutics Inc's Peers' Costs of Sales and Capital Expenditures
Context for revenue growth: peer costs and capex, year over year and quarter over quarter| Company | Period | Costs Y/Y | Capex Y/Y |
|---|---|---|---|
| Soleno Therapeutics Inc | Q1 2026 | - | +700.0 % |
| Amicus Therapeutics inc | Q4 2025 | +80.0 % | +3.8 % |
| Zymeworks Inc | Q2 2026 | - | - |
| Ocean Biomedical Inc | Q1 2025 | - | - |
Soleno Therapeutics Inc's Returns and Turnover vs Peers
ROA, ROI and ROE (trailing 12 months), receivables and inventory turnover| Company | ROA | ROI | ROE |
|---|---|---|---|
| Soleno Therapeutics Inc | 18.25% | 19.51% | 22.85% |
| Amicus Therapeutics inc | - | - | - |
| Zymeworks Inc | - | - | - |
| Ocean Biomedical Inc | - | - | - |
ROA = net income / total assets; ROI = net income / investments; ROE = net income / equity; turnover ratios use trailing 12 month revenue (receivables) and cost of sales (inventory).
Soleno Therapeutics Inc's Valuation vs Peers
P/E, price to sales, PEG, price to cash flow and price to book| Company | P/E | Price / Sales |
|---|---|---|
| Soleno Therapeutics Inc | 29.45 | 9.87 |
| Amicus Therapeutics inc | - | 7.06 |
| Zymeworks Inc | - | 58.82 |
| Ocean Biomedical Inc | - | - |
| PEERS AVERAGE | - | 9.91 |
P/E = price / diluted EPS (trailing 12 months); PEG = P/E divided by EPS growth; the average row divides the peers' combined market cap by their combined income, sales, cash flow and equity.